, 4-5 (van Bommel, 2017), (), 2 , FDA
Common Side Effects Reported Across Phase 2 trials, participants experienced dose-dependent GI symptoms that are characteristic of GLP-1 receptor agonists: Nausea most frequent, especially during dose escalation Vomiting typically mild to moderate, subsiding with continued use Diarrhea and constipation fluctuating depending on individual tolerance Abdominal discomfort transient and often improved over time Dose-Response Relationship At lower doses (14 mg weekly), side effects were generally mild and manageable, though some participants still reported early GI symptoms
With current research, activation of these receptors has overall reduced caloric intake and increased energy expenditure, successfully leading to higher weight loss compared to alternative treatments
Hormone replacement therapy (HRT) for midlife women How do you approach HRT for perimenopausal and menopausal women
Wharton et al., 2022
Biomarkers like baseline fasting glucose, HbA1c, and inflammatory markers also correlate with GLP-1 tolerability
